Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Mutations: Optimizing the Patient Experience

  H&O  What is the mechanism of action of enasidenib? GR Enasidenib (Idhifa, Celgene/Agios) is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) […]

Enasidenib for Patients With Relapsed Acute Myeloid Leukemia and the IDH2 Mutation

  H&O  Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]

Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches

  Abstract: It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances […]